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1. Introduction  
“Diarrhea is the passage of 3 or more loose or liquid stool per day, or more frequently than 
is normal for the individual. It is usually a symptom of gastrointestinal infection, which can 
be caused by a variety of bacterial, viral and parasitic organisms, infection is spread through 
contaminated food or drinking-water, or from person to person as a result of poor hygiene” 
(WHO). Diarrheal diseases affect all races, sexes, ages and geographic areas, has high impact 
on mortality and morbidity worldwide, an estimated 2-4 billion episodes of infectious 
diarrhea occurred each year and are especially prevalent in infants (Hodges and Gill 2010; 
Farthing 2002). In 2005, 1.8 million people died worldwide from diarrheal diseases (WHO, 
2007). In México, in the past 6 years, the gastrointestinal infection has been a serious health 
problem and was the second cause of morbidity among all age groups (SS, 2008).  
2. Pathophysiology classification of diarrhea 
 Osmotic; is caused by poorly absorbable solutes (eg. sorbitol, magnesium salts) 
remaining in the gastrointestinal lumen retain water and electrolytes resulting in 
reduced water reabsorption 
 Altered Motility; caused slowing of the motor function of the small intestine as with 
narcotic use, scleroderma, diabetic autonomic neuropathy and amyloidosis 
 Exudative; the intestinal epithelium’s barrier function is compromised by loss of 
epithelial cells or disruption of tight junctions (eg. E. coli, Salmonella, Shigella, Yersinia, 
Campilobacter, Mycobacteryum tuberculosis, Clostridium difficile y Entamoeba histolytica), 
inflammatory disease process as in ulcerative colitis and Crohn’s disease  
 Secretory; is caused by an increase in water and electrolytes (Chloride or bicarbonate) 
movements to the intestinal lumen, the final effect is the increase of secretion and 
decrease of absorption of net sodium and water (Navaneethan and Giannella, 2010). 
2.1 Secretory diarrhea 
Secretory diarrhea occurs when the balance between absorption and secretion in the small 
intestine is disturbed by excessive secretion caused by bacterial enterotoxins, is a net 
movement from mucous intestinal to lumen, the volume exceed 10 mL/Kg/day, and the 
osmolarity is similar with plasma. It is the leading cause of death in infants in developing 
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countries and currently accounts for an estimated of three million deaths each year among 
under 5 years old children (Casburne-Jones and Farthing, 2004; Filbin 2004). Most causes of 
secretory diarrhea alter the second messenger system through alteration in cAMP, cGMP or 
intracellular calcium regulated ion transport pathways, alterations in these mediators cause 
CFTR-mediated Cl- secretion an inhibition of small intestinal-coupled Na+-Cl- transport 
(Navaneethan and Giannella, 2010) 
2.1.1 Secretory diarrhea noninfectious 
Some of these include  
 Tumors (pancreatic islet, which secrete vasoactive intestinal peptide (VIP), 
carcinoid which elaborate serotonin, bradykinin, substance P and prostaglandins, 
medullary carcinoma of thyroid-secreting calcitonin) 
 Neurotransmitters are also potent secretory stimuli, such as histamine in systemic 
mastocytosis and inflammatory cytokines 
 Malabsorbed bile salts and fatty acids (hydroxyl fatty acids also stimulate colonic 
secretion) 
 The congenital absence or alterations in the numerous transporters that maintain 
the constant flux of the ions and water 
 Rare congenital syndromes: congenital chloridorrhea, there is a defect in brush 
border Cl-/HCO3- exchange in the ileum and the colon and hence impaired 
absorption of chloride, congenital sodium diarrhea results from a congenital defect 
in Na+-bile acid absorption in the colon (Navaneethan and Giannella, 2010; Filbin 
2004) 
2.1.2 Secretory diarrhea caused by pathogens 
Microbial causes include rotavirus, norovirus, Cryptosporidium, its affects the absorptive villi 
inhibiting sodium absorption. Enterotoxigenic E. coli (ETEC), V. cholera elaborate 
enterotoxins that stimulate intestinal chloride secretion along with impaired sodium 
absorption, Giardia lambia adhere to the mucosa disrupting the absorptive/secretary process 
of enterocyte producing active secretion (Navaneethan and Giannella, 2010) 
2.1.2.1 Enterotoxigenic bacteria 
 Vibrio cholerae 
 Enterotoxigenic Escherichia coli 
 Clostridium perfringes 
 C. botulinum 
 Campylobacter jejuni 
 Klepsiella pneumoniae 
 Aeromonas hydrophila 
 Yersinia enterocolitic 
2.1.2.2 Enteroinvasive bacteria 
 Enteroinvasive Escherichia coli 
 Salmonella typhi 
 S. enteritidis 
 Shigella spp 
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 Campylobacter jejuni 
 Plesiomonas shigeloids 
 Yersinia enterocolitic 
 Vibrio parahaemolyticus 
2.1.2.3 Viruses 
 Group A rotaviruses, G1 and G serotypes 
 Norovirus (old term of Nolwalk virus) 
 Parvoviruses (Hawai, Colorado, Ditchilling 
 Enteric adenoviruses 40 and 41 
 Coronaviruses 
 Calciviruses 
 Astroviruses 
2.1.2.4 Parasites 
 Gardia lamblia 
 Entamoeba histolityca 
 Cryptosporidium parvum 
 Isospore belli 
 Sarcosystis sp 
 Cyclospore cayetanensis 
 Blastocystis hominis 
 Microsporidie 
2.2 Diarrhea caused by enterotoxins 
A number of several bacteria cause diarrhea by the production of potent enterotoxins, such 
as enterotoxigenic Escherichia coli, Salmonella typhi, S. typhimurium, clostridium difficile, 
C. freundii, Aeromonas hydrophila, Yersinia enterocolic, Camphylobacter jejuni and Vibrio 
cholera. Enterotoxins have their effect on the enterocyte functions by stimulating the 
secretion of transepitelial electrolytes, increasing the osmotic flux of water and ions to the 
intestinal lumen, specifically, heat-labile (LT) and heat stable (ST) enterotoxins from E. coli, 
V. cholera and C. jejuni increase net fluid secretion by affecting the enzymes adenylate 
cyclase or guanilate cyclase by activation of the cAMP (cyclic 3’,5’-adenosine 
monophosphate) in the mucosal epithelium which induces an increase of intestinal secretion 
and causes diarrhea.(Casburn-Jones and Farthing 2004, Amstrong and Cohen, 1999). 
2.2.1 Vibrio cholerae enterotoxin 
Vibrio cholerae enterotoxin is an oligomeric protein which is composed by two subunits, A 
subunit of 27.2 KDa composed as A1 and A2 subunits, and B subunit composed by five 
subunits B of 11.6 KDa each one, AB5 complex Fig 1. (Sixma, 1991) 
2.2.2 Vibrio cholerae enterotoxin mechanism 
Mechanisms proposed to secretory diarrhea caused by V. cholera enterotoxin involves the 
union of subunits B to the oligosaccharide portion of the receptor GM1, present in the apical 
surface of enterocytes, this union lend the entrance of A subunit of toxin to the enterocyte 
for acidic endosomes, which pick up the golgi apparatus and endoplasmic reticulum, 
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Fig. 1. Vibrio cholerae enterotoxin AB5 complex 
inside of enterocyte disulphure bond between A1-A2 is dissolved by protein disulfide 
isomerase, it causes release of A1 which is capable of binding NAD and catalyzing the 
NADP-ribosylation of Gs, a GTP-binding regulatory protein associated with adenylate 
cyclase. A1 subunit stimulates increasing of 1000 times production of cAMP second 
messenger, cAMP active protein cinase A, which phosphorile and activate transmembranal 
chloride channels of the enterocytes located on intestinal crypts, it causes massive secretion 
of water and electrolytes to intestinal lumen, in villus cell there is a decrease of absorption of 
Na+ and Cl- ions (Kopic 2010). Fig 2. shows the proposed mechanism to the action of Vibrio 
Cholerae enterotoxin. At 5 to 10 minutes to the exposure of V. cholera toxin cause intestinal 
hypersecretion of water and electrolytes for several hours (Thiagarajah, 2005; Spangler, 
1992). The symptoms are manifested as severe cramp and the copious “rice water” diarrhea 
characteristic of the disease. 
2.3 Dehydration 
During diarrhea there is an increased loss of water and electrolytes (sodium, chloride, 
potassium and bicarbonate) in the liquid stool; dehydration occurs when these losses are not 
replaced adequately and a deficit of water and electrolytes develops. The degree of 
dehydration is graded according to signs and symptoms that reflect the amount of fluid lost: 
 In the early stages of dehydration, there are no signs or symptoms 
 As dehydration increases, signs and symptoms develop. Initially these include: thirst, 
restless or irritable behavior, decreased skin turgor, sunken eyes, and sunken fontanel 
(in infants). 
 In severe dehydration, these effects become more pronounced and the patient may 
develop evidence of hypovolemic shock, including: diminished consciousness, lack of 
urine output, cool moist extremities, a rapid feeble pulse, low or undetectable blood 
pressure, and peripheral cyanosis.  
 Death follows soon if rehydration is not started quickly (WHO, 2005). 
2.4 Secretory diarrhea treatment 
2.4.1 Oral rehydration 
To control diarrhea disease, a sufficient hydration of the patient should be procure and 
provide the necessary ions to maintain electrolyte balance, the treatment of choice is oral 
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Fig. 2. Cholera toxin mechanism proposed by Velázquez  et al., A1,2 B5 (subunits), GM1 
(ganglioside receptor) , Gs (G protein),  cAMP (cyclic AMP), CFTR (cystic fibrosis 
transmembrane conductance regulator). 
rehydration solution (ORS), it has reduced the levels of mortality in children and elderly by 
dehydration, but not morbidity (Turvill et al., 2000), the treatment is based by active 
absorption of glucose by smooth intestine, during the intestinal infection lend to the co-
transport of Na+ ions and water absorption. WHO and UNICEF guidelines recommend their 
use, is important to notice that ORS, is useful to treat dehydration caused by diarrhea, but it 
not decrease the amount and duration at the same. Depends of severity of diarrhea, in some 
cases ORS is not enough and antibiotic, spasmolytic, and antiprotozoal drugs should be 
used. WHO recommended use of secure and effective drugs to the pediatrics (Marion et al., 
2010). 
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2.4.2 Drugs used to treat secretory diarrhea 
To treat the secretory diarrhea there are some drugs which reduce the intestinal movement 
such as codeine (1), loperamide (2), diphenoxylate (3), lidamidine (4), bismuth subsalicylate 
(5), racecadotril (6) and clonidine (7) Table 1.; which are capable to stimulate absorption 
direct and reduce secretion of water and electrolytes in gastrointestinal tract, to decrease 
propulsion, contact time of intestinal content with mucosal surface increase, it favors the 
absorption. They act not premised release of prostaglandins too (Marion et al., 2010; 
Martindale 2009). 
 
Structure Effect 
 
Codeine (1) 
Has a high antidiarrheal action but, produces 
secondary effects such as nauseas, dizziness and 
acts against central nervous system, it can be used 
carefully in children, continuous use can induce 
physical dependence and addiction 
Loperamide (2) 
Decrease intestinal motility and present 
antisecretory effect by activation of calmodulin, 
increase the water and electrolytes absorption to 
the intestinal lumen. It should not be 
administrated to children under six years old, 
patients with constipation, atony or intestinal 
obstruction, should avoid its use on bacterial 
infective severe and in acute dysentery. Frequent 
adverse reactions induced are hypersensibility 
reactions (cutaneous eruption), gastrointestinal 
disorders (constipation, colic, abdominal 
distention, nauseas and vomit), fiver and dry 
mouth, is a non-prescription drug for children 
because can cause CNS depression 
 
diphenoxylate (3) 
Inhibits intestinal propulsion and fecal excretion 
velocity, cause decrease of intestinal transit, to 
therapeutic doses it induces adverse reactions in 
central nervous system (confusion, sedation, 
depletion, cephalea), allergic reactions (anaphylaxis, 
prurite) on gastrointestinal apparatus (toxic 
megacolon, paralytic ileum, vomit, nauseas and 
abdominal pain) It can cause euphoria and has 
analgesic effect. Difenoxilate is contraindicated in 
children younger than 2 years old. 
 
Lidamidine (4) 
Improve the absorption of water and electrolytes 
in intestinal velocities and reverse their secretion 
to level on intestinal crypts. 
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Structure Effect 
 
 
 
Bismuth subsalicylate (5) 
Showed antisecretor effect for the inhibition of 
prostaglandins, reduce depositions number and 
reduce abdominal pain, causes adverse reactions 
(dizziness, cephalea, constipation, dark stools, 
ataxia, tremor, encephalopathy, confusion, 
delirium and convulsions). 
 
 
 
Racecadotril (6) 
Decrease intestinal hipersecretion of water and 
electrolytes to intestinal lumen, inhibits release of 
encephalinse endogenus witch act on opiaceus 
receptors  decreasing cAMP level (decrease water 
and electrolytes secretion), cause some adverse 
reactions such as hypokalemia, bronchospasm, 
fever, vomit and otitis.  
 
 
 
Clonidine (7) 
Stimulates sodium and chloride absorption and 
inhibits chloride secretion by interaction with its 
receptor on enterocyte, causes an alteration of gut 
motility with effect on intestinal transport, it 
causes hypotension 
Table 1. Drugs used to treat secretory diarrhea 
On the other hand, there are some compounds that showed inhibitory properties on the 
intestinal secretion Fig 3. such as berberine (8), chlorpromazine (9), nicotinic acid (10), 
indomethacin (11), somatostatin (12) and ethacrinic acid (13) but they were not developed as 
antidiarrhoeal drugs (Fedorack and Field, 1987). Thus, the research for new antisecretory 
agents that should be effective and safe to treat diarrhea is still a necessary goal. 
 
 
          
                        berberine 8                                           chlorpromazine  9 
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         nicotinic acid  10                                                 Indomethacin 11 
 
 
somatostatin 12 
 
 
ethacrinic acid 13 
Fig. 3. Compounds with inhibitory properties on the intestinal secretion 
2.4.3 Potential target areas to design therapeutic agents on Vibrio cholerae toxin 
During the last two decades there has been a continuous research of drugs that inhibit the 
secretory process in the enterocyte to help to the control of diarrhea, but only a few 
candidates have emerged, and none has found a place in the routine management of 
secretory diarrhea. Particularly to cholera toxin its mechanism of action revel several 
potential target areas to design therapeutic agents such as: 
a. The inhibition of adenylate cyclase 
b. The blockage of the active site of the enzyme located in the A subunit 
c. The disruption of the assembly of the holotoxin by interrupting the A2-B interaction  
d. The interception of the receptor binding to the bottom of the B pentamer (Guangtao Z., 
2009). 
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e. Inhibitors of enkephalinase and of the cystic fibrosis transmembrane conductance 
regulator (Thiagarajah, 2005). 
f. Inhibition of transport proteins involved in cAMP activated chloride secretion 
 
 
 
Fig. 4. Synergism of structure-based drug design with combinatorial chemistry for the 
design of receptor antagonist of cholera toxin 
http://www.bmsc.washington.edu/WimHol/figures/figs2/WimFigs2.html 
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2.5 Medicinal plants as a source of antidiarrheal compounds 
Diarrheal diseases are a health problem because affect a large number of the population 
mainly children and elderly. In México the use of medicinal plants to treat gastrointestinal 
disorders including diarrhea occupied the first place, there are few pharmacological and 
chemical studies which support their use. Approximately 80% of the world’s population 
uses medicinal plants to treat immediately health problems, is clear the importance of 
multidisciplinary research of our natural sources. The study of medicinal plants with the 
propose to provide pharmacological evidence that may explain its therapeutic use  
There are some in vitro models such as isolated ileum of guinea pig, isolated jejune of rabbit, 
ileum and duodenum isolated of rat or rabbit and in vivo reduction of intestinal motility using 
charcoal meal, Castor oil, PGE2, MgSO4 induced diarrhea, and Enteropooling models. 
Antispasmodic activity has been demonstrate for some flavonoids such as quercetin, 
quercitrin, genistein, sakuranetin, rutin and bisabolol; terpenoids such as himachalol, coleonol, 
-damascenone, -fitol, capsidiol, -eudemol, hinesol, huatriwaico acid, camaldulin and tymol; 
essential oils such as, 1,8-cineol, eugeol, timol, carvacrol, estragolanetol,  y  pinenes, 
nonanal, and linalool; alkaloids such as himbacine, protopine, coptisine, cantleyine, 
mitraginine, vertine, retuline, cavidine and metuenine (Astudillo et al., 2009). 
There are a great number of natural remedies for diarrhea control, historically Papaver 
somniferum preparations are efficient and powerful against diarrhea, as the derivative 
codeine, alkaloids are ones of major substances explored form natural products and they 
give to pharmaceutical industry a big number of patents, another class of compound 
explored therapeutically are flavonoids and has been used as complement in treatment of 
cancer, heart diseases, venous insufficiency, venous ulcers, hemorrhoids and diarrhea. 
(Martindale 2009) 
2.5.1 Antisecretory compounds isolated from medicinal plants 
Some studies have been performed in order to find antisecretory compounds from several 
plants used in traditional medicine to treat several kinds of diarrheas. In this sense the 
extracts from Croton urucurana, C. lechleri, Berberis aristata and Guazuma ulmifolia were 
studied against intestinal secretion caused by V. cholera toxin, in the cases of C. lechleri, B. 
aristata and G. ulmifolia the isolated compounds were oligomeric proantocyanidins and 
berberine, respectively. From C. urucurana saponins, steroids, alkaloids, antocianidins and 
catechins have been isolated. Prontocianidins and catechins probably can be associated with 
their antisecretory activity. 
Steviol (29) and dihydroisosteviol (30) can inhibit cAMP-activated chloride secretion in 
human’s intestine cells by targeting CFTR (Pariwat 2008). Penta-m-digalloyl-glucose (PDG) 
(31) isolated of Chinese gallnuts showed efficacy in reducing enterotoxin-induced intestinal 
fluid secretion in mice (Wongsamitkul et al., 2010) 
 
 
                                   Steviol 29                                       dihydroisosteviol  30 
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Crofelemer (32) is a proanthocyanidin oligomer obtained from Croton lechleri  (dragon’s 
blood), the sap has been used to treat diarrheas including dysentery and cholera, 
pharmacological studies have shown that it reduces fluid secretion in cell culture and 
mouse models (Gabriel et al., 1999), it has been reported that the antisecretory mechanism 
of action of crofelemer involves dual inhibition of The cystic fibrosis transmembrane 
regulator conductance  (CFTR), a cAMP stimulated Cl- channel, and calcium-activated Cl- 
channels (CaCC) at the luminal membrane of enterocytes ( preliminary studies showed 
that crofelemer (32)  may reduce watery stool output in patients with infectious diarrhea 
such as cholera. But it needs further Phase 3 clinical trials are still necessaries (Crutchley 
et al., 2010). 
 
 
Penta-m-digalloyl-glucose (PDG) (31)                                 Crofelemer (32) 
We continue with the research of compounds with antisecretory activity useful to treat 
diarrhea. Medicinal plants used in Mexican traditional medicine to treat gastrointestinal 
disorders could be a source of compounds with therapeutic utility. In México, the use of 
medicinal plants to treat gastrointestinal disorders such as diarrhea and dysentery is 
widespread (Aguilar et al., 1994). However most of these plants have not been investigated 
from a pharmacological point of view to demonstrate their antisecretory properties, which 
could lead to support their use as antidiarrheal and anti-dysenteric drug in traditional 
medicine. We screened aqueous and methanol extracts from 26 Mexican medicinal plants to 
assess their antisecretory activity using the cholera toxin-induced intestinal secretion in rat 
jejunal loops model. None of this species or their isolated compounds has been previously 
evaluated as antisecretory agents (Velázquez et al., 2006). 
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2.5.2 Material and methods 
2.5.2.1 Plant materials 
The plants used in that study were collected from different regions in Mexico: Mexico City, 
States of Hidalgo, Mexico, Sinaloa, Guanajuato and Yucatan, all of them were selected 
according to their use in Mexican traditional medicine to treat gastrointestinal disorders. 
Voucher herbarium specimens were deposited in Herbarium IMSSM of Instituto Mexicano 
del Seguro Social and were authenticated by MS Abigail Aguilar. 
2.5.2.2 Preparation of crude extracts 
The air-dried plant material (20g) was extracted by maceration with 300 mL of MeOH for 1 
week. Then the macerate was filtered and concentrated under reduced pressure at 40°C. For 
aqueous extracts, 20 g of air-dried plant material were extracted by decoction with 100 mL 
of distilled water for 30 min, the solution was filtered and lyophilized.  
2.5.2.3 Cholera toxin 
Lyophilized powder (1mg) of Cholera toxin (SIGMA) containing approximately 220,000 
units/mg of protein was suspended in 1 mL of sterile water. Aliquots of the toxin solution 
were dissolved in a 1x PBS (NaCl 8g, KCl 0.2 g, Na2HPO4.7H2O o.115 g, KH2PO4 0.2 g/L) 
solution with 1% bovine serum albumin (SIGMA) to obtain a concentration of 3 g/mL. 
2.5.2.4 Antisecretory assay 
The antisecretory activity of the extracts was tested using a method described by Torres et 
al., in 1993. Briefly, male Sprague-Dawley rats (200-250 g) were obtained from the animal 
house of the IMSS. The experimental protocols were in accordance with the official Mexican 
norm NOM 0062-ZOO-1999 entitled technical specifications for the production, care and use 
of laboratory animals (SAGARPA 2001). The antisecretory effect of the extract was studied 
on intestinal secretion indirectly by measuring the fluid accumulation in the intestine 
following cholera toxin administration to rats. Two jejuna loops were prepared in the rats 
and inoculated with 3 g/mL of cholera toxin dissolved in 1x PBS with 1 % bovine albumin. 
Rats (n=4 per group by duplicated) were treated orally with each extract (300 mg/Kg in 1 
mL of a 2 % DMSO solution in water). Loperamide (10 mg/Kg) was used as antidiarrhoeal 
drug. After 4 h, the animals were sacrificed using ethyl ether. The antisecretory activity of 
the extracts was measured as the fluid accumulation in the loops and expressed in 
percentage of inhibition. Values are expressed as mean ± SEM. Statistical significance was 
determinate using Mann-Whitney U-test. Values with p<0.05 were considered significant. 
2.5.2.5 Results 
We tested 56 aqueous and methanol crude extracts obtained from 26 medicinal plants used 
in Mexican traditional medicine for the treatment of gastrointestinal disorders. The 
antisecretory activity was tested using the cholera toxin-induced intestinal secretion in rat 
jejunal loops model. Only the principal antisecretory activity of the extracts tested is shown 
in Table 2, the full list is showed in Velázquez et al., 2006. 
In traditional medicine since infusions or decoctions are usually taken three times per day 
when diarrhea occurs, our results can be related with their traditional use because the used 
dose is approximately one cup of plant tea which is recommended by Mexican people to 
treat gastrointestinal disorders (Aguilar et al., 1994).We found that both extracts from 
Chiranthodendron pentadactylon, Hippocratea excelsa and Ocimum basilicum were the most 
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active with inhibition values ranging from 68.0 to 87.6% at 300 mg/kg. Methanol extract of 
Geranium mexicanum (aerial parts) and the aqueous extract of Bocconia frutescens were active 
too with inhibition values of 93.4 and 86.0%, respectively. On the other hand, the methanol 
extract of Chenopodium ambrosioides green variety (aerial parts), Lygodium venustum, Punica 
granatum and Ruta chalepensis, the aqueous extracts of Aloysia triphylla, Chenopodium 
ambrosioides green variety (aerial parts), Dorstenia contrajerva and Schinus molle shown 
inhibitory activity with values ranging from 43.4 to 79.5%. The 87% of the extracts tested 
showed inhibitory activity of the intestinal secretion; only seven extracts did not show any 
antisecretory activity. In general, among the researched extracts, the methanol extracts 
exhibited the highest antisecretory activity. 
 
Family Plant specie Part 
used 
Voucher 
number
Extract % Inhibition 
Verbenaceae Aloysia triphylla (L’Hér) Britton AP 126110 Methanol 
Aqueous
7.8± 4.7 
80.4±22.8 
Papaveraceae Bocconia frutescensL. AP 12618 Methanol 
Aqueous
24.1±15.4 
86.0± 9.8 
Chenopodiaceae Chenopodium ambrosioides L., 
green variety 
AP 14402 Methanol 
Aqueous
43.4 ±6.5 
48.7 ±11.6 
Sterculiaceae Chiranthodendron pentadactylon 
Larreat 
F 14104 Methanol 
Aqueous
87.6± 15.3 
84.8 ±17.4 
Moraceae Dorstenia contrajerva L. AP 14406 Methanol 
Aqueous
24.4±16.4 
44.8± 5.9 
Geraniaceae Geranium mexicanum H. B. & K. AP 14405 Methanol 
Aqueous
93.4 ±6.7 
42.1±15.2 
Hippocrateaceae Hippocratea excels H. B. & K. R 14394 Methanol 
Aqueous
80.3 ±21.3 
75.0 ±24.9 
Schizaeaceae Lygodium venustum Sw. AP 1270 Methanol 
Aqueous
51.6±15.6 
0 
Labiatae Ocimum basilicum L. AP 14393 Methanol 
Aqueous
68.7 ±9.7 
68.0±20.8 
Punicaceae Punica granatum L. EF 14403 Methanol 
Aqueous
55.9 ±3.6 
19.1 ±6.9 
Rutaceae Ruta chalepensis L. AP 14400 Methanol 
Aqueous
73.7 ±.01 
23.6 ±9.27 
Anacardiaceae Schinus molle L. AP 14408 Methanol 
Aqueous
0 
79.5±17.7 
Table 2. Antisecretory activity of methanol and aqueous extracts of Mexican medicinal 
plants on intestinal secretion response to cholera toxin, AP: aerial parts, EF: fruit exocarpus, 
F: flowers, R: roots. 
2.6 Antisecretory study of Chiranthodendron penthadactylon 
We selected Chiranthodendron pentadactylon Larreat (Sterculiaceae) to perform bio-guided 
assay fractionation. C. pentadactylon know in Mexico as “flor de manita”has been used  
in Mexican traditional medicine since Aztecs ancient times to treat heart illness, epilepsy, 
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diarrhea and dysentery (Linares et al., 1988, Argueta et al., 1994). This study lend to  
the isolation of some compounds with in vivo antisecretory activity (Velázquez et al., 
2009).   
2.6.1 Isolation of active compounds 
The flowers of C. pentadactylon were ground and extracted by maceration at room 
temperature with methanol, the extract was suspended in 10 % MeOH-water and 
successively partitioned with CH2Cl2 and EtOAc, the aqueous residual layer was 
lyophilized. The fractions were tested for antisecretory activity at doses of 50 mg/Kg. The 
most active fraction was AcOEt with 88.2 % of Inhibition. In order to isolate the active 
compounds, it was subjected to column chromatogaphy on Sephadex (Pharmacie) using 
CHCl3 in EtOH, MeOH and Water to give eight secondary fractions, further 
chromatography lend to the isolation of tiliroside (33), astragalin (34), isoquercitrin (35), (+) 
catechin (36), and (-) epicatechin (37). All the isolated compounds were identified by 
comparison of spectroscopic data (1H and 13C NMR, UV, IR, [], and TLC and HPLC with 
authentic samples available in our laboratory (Kuroyanagui et al., 1978; Lee et al., 1992; Lui 
et al., 1999; Calzada et al., 2007). 
2.6.2 Antisecretory activity of isolated compounds 
Antisecretory activity of the isolated compounds from the AcOEt fraction was tested on 
cholera toxin-induced intestinal secretion in rat jejunal loops model (table 3). Among the 
isolated compounds (-) epicatechin (37) showed the best antisecretory activity on the 
intestinal secretion with an ID50 of 8.3 M /mL, its antisecretory activity was like of 
loperamide (2) (ID50 6.1 M/mL), isoquercitrin (35) and (+)-catechin (36) showed moderate 
and weak antisecretory activity, respectively. Tiliroside (33) and astragalin (34) were 
inactive at doses tested table 3. Flavonoids such as flavan-3-ols and flavonol glycosides have 
been considered as the active principles of many antidiarrheal plants. Isoquercitrin isolated 
from Psidium guajava showed spasmolytic effect on guinea pig ileum (Morales et al., 1994). 
Tiliroside (33) and (-)-epicatechin (37) obtained from Helianthemum glomeratum and Rubus 
coriifolius, respectively, showed antiprotozoal activity against Entamoeba histolytica and 
Giardia lamblia (Alanis et al., 2003; Barbosa et al., 2007). Data obtained in this investigation 
suggest that (-)-epicatechine (37), isoquercitrin (35) and tiliroside (33) may play an important 
role in antidiarrheal of C. penthadactylon in Mexican traditional medicine. Also, our results 
are in agreement and could explain the result previously obtained by Hör et al., 1995, with 
antisecretory oligomeric proantocianidins from Guazuma ulmifolia which monomeric unit are 
(+)-catechin (36) and (-)-epicatechin (37). The antiprotozoal activity together with the 
antisecretory activity is evidences that support the use of these plants to treat diarrhea in 
Mexican traditional medicine. 
Further studies are carried on in order to determinate the action mechanism of active 
compounds against intestinal secretion caused by Vibrio cholerae toxin (non publicated 
results), Additionally we are studying some medicinal plants used to treat gastrointestinal 
disorders in Mexican traditional medicine from Hidalgo, using intestinal propulsion 
(charcoal meal), castor oil induced diarrhea and castor oil induced intestinal fluid 
accumulation models in vivo. 
www.intechopen.com
 
Management of Secretory Diarrhea 
 
81 
      
tiliroside 33                                            astragalin 34 
     
Isoquercitrin (35)    (+)-catechin (36) 
   
(-) epicatechin (37)    loperamide (2) 
www.intechopen.com
 
Current Concepts in Colonic Disorders 
 
82
Compound 
Doses 
(mg/Kg) 
% of 
Inhibition 
ID50 
(M/Kg) 
MeOH extract 300 87.1 14.5 - 
EtOAc fraction 50 88.2 9.5 - 
Tiliroside (33) 10 - Inactive 
Astragalin (34) 10 - Inactive 
Isoquercitrin (35) 10 - 19.2 
(+)-catechin (36) 10 - 51.7 
(-)-epicatechin (37) 10 - 8.3 
Loperamide (2) 10 - 6.1 
Table 3. Antisecretory activity of MeOH extract, EtOAc fraction and isolated compounds 
from Chiranthodendron pentadactylon 
3. Conclusion 
Some of the medicinal plants tested showed antidiarrheal activity in the model used. Both 
extracts of Annona cherimola, Chiranthodendron pentadactylon, Hippocratea excelsa, Ocimum 
basilicum, Geranium mexicanum (aerial parts), methanol extract of Ruta chalepensis, Lygodium 
venustum, Punica granatum, and the aqueous extract of Bocconia frutescens, Aloysia triphylla, 
Dorstenia contrajerva and Schinus molle showed better antisecretory activity than loperamide. 
The active extracts found in this study will be an option to develop novel phytodrugs useful 
to treat fluid loss in diarrhea. These results allows to propose these species as a potential 
sources of antisecretory compounds and should be therefore subjected to further bioassay-
guided phytochemical studies to obtain their active principles, the antisecretory compounds 
isolated from medicinal plants combined with ORS might be useful in decreasing the 
mortality caused by dehydration. The properties previously described of (-)-epicatechin 
suggest that it may be a leading compounds in the development of novel antidiarrheal 
agents. The results obtained give some scientific support to the use of some medicinal plants 
tested for the treatment of gastrointestinal disorders such as diarrhea. 
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